Encompass Health (AMEX:EHC) updated its FY18 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $3.25 to $3.40 for the period, compared to the Thomson Reuters consensus estimate of $3.38. The company issued revenue guidance of $4150 to $4250, compared to the consensus revenue estimate of $4.19 billion.
Shares of Encompass Health (EHC) traded up $0.31 during trading on Wednesday, reaching $57.34. The company had a trading volume of 22,406 shares, compared to its average volume of 550,873. Encompass Health has a 1 year low of $40.86 and a 1 year high of $57.41. The stock has a market cap of $5,640.00, a P/E ratio of 21.16, a P/E/G ratio of 1.70 and a beta of 0.48. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.34 and a current ratio of 1.34.
Encompass Health (AMEX:EHC) last posted its earnings results on Monday, February 26th. The company reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.06. Encompass Health had a net margin of 8.67% and a return on equity of 23.56%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the firm earned $0.72 EPS. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. research analysts forecast that Encompass Health will post 2.72 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Monday, April 2nd will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, March 29th. This represents a $1.00 annualized dividend and a dividend yield of 1.74%. Encompass Health’s dividend payout ratio is currently 36.90%.
Several equities analysts have commented on EHC shares. Royal Bank of Canada reissued a buy rating on shares of Encompass Health in a research report on Wednesday, November 15th. Zacks Investment Research lowered shares of Encompass Health from a hold rating to a sell rating in a research note on Saturday, December 30th. Stephens set a $62.00 price target on shares of Encompass Health and gave the stock a buy rating in a research note on Tuesday, February 27th. Piper Jaffray Companies restated a hold rating and set a $59.00 price target on shares of Encompass Health in a research note on Thursday, March 1st. Finally, Credit Suisse Group raised their price target on shares of Encompass Health from $58.00 to $61.00 and gave the stock an outperform rating in a research note on Tuesday, February 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. Encompass Health presently has a consensus rating of Hold and a consensus target price of $58.00.
About Encompass Health
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.